Skip to main content

Marcus Joel S's Form 4 filing

Intra-Cellular Therapies, Inc.ITCI · filed Feb 27, 2024

Accession no.
0000950170-24-021563
Filed
Feb 27, 2024
Trade date
Feb 26, 2024
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.81M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Marcus Joel SCIK 0001216955Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 26, 2024Common StockMOption exerciseAcquired+20,000$43.45+$869,00049,233Direct
Feb 26, 2024Common StockMOption exerciseAcquired+16,757$55.48+$929,678.3665,990Direct
Feb 26, 2024Common StockSSaleDisposed−8,371$67.83F1−$567,804.9357,619Direct
Feb 26, 2024Common StockSSaleDisposed−17,658$69.07F2−$1,219,638.0639,961Direct
Feb 26, 2024Common StockSSaleDisposed−299$69.60F3−$20,810.439,662Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 26, 2024Common StockMOption exerciseDisposed−20,000$0.00$00Direct
Feb 26, 2024Common StockMOption exerciseDisposed−16,757$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.53 to $68.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.53 to $69.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)